ResMed Company Profile (NYSE:RMD)

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:RMD
  • CUSIP: 76115210
  • Web: www.resmed.com
Capitalization:
  • Market Cap: $11.23 billion
  • Outstanding Shares: 142,209,000
Average Prices:
  • 50 Day Moving Avg: $77.98
  • 200 Day Moving Avg: $74.36
  • 52 Week Range: $56.59 - $81.87
P/E:
  • Trailing P/E Ratio: 32.92
  • Foreward P/E Ratio: 23.24
  • P/E Growth: 2.54
Sales & Book Value:
  • Annual Revenue: $2.07 billion
  • Price / Sales: 5.43
  • Book Value: $13.79 per share
  • Price / Book: 5.73
Dividend:
  • Annual Dividend: $1.40
  • Dividend Yield: 1.8%
Profitability:
  • EBITDA: $568.89 million
  • Net Margins: 16.56%
  • Return on Equity: 21.99%
  • Return on Assets: 11.86%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 4.57%
  • Quick Ratio: 3.82%
Misc:
  • Average Volume: 1.16 million shs.
  • Beta: 0.77
  • Short Ratio: 13.12
 

Frequently Asked Questions for ResMed (NYSE:RMD)

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Wednesday, August 2nd. Stockholders of record on Thursday, August 17th will be given a dividend of $0.35 per share on Thursday, September 21st. This represents a $1.40 annualized dividend and a dividend yield of 1.77%. The ex-dividend date is Tuesday, August 15th. This is an increase from ResMed's previous quarterly dividend of $0.33. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Tuesday, August, 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.02. The business earned $556.69 million during the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The company's quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 earnings per share. View ResMed's Earnings History.

When will ResMed make its next earnings announcement?

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for ResMed.

Where is ResMed's stock going? Where will ResMed's stock price be in 2017?

10 brokers have issued twelve-month price targets for ResMed's stock. Their predictions range from $56.00 to $71.00. On average, they anticipate ResMed's stock price to reach $64.80 in the next year. View Analyst Ratings for ResMed.

What are analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "ResMed achieved strong global revenue growth over the past few quarters, led by sales of sleep devices, respiratory care devices, mask systems and software solutions. Also, Brightree has acted as a significant contributor to the company’s operating results through 2017. Notably, we believe, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance further in the near term. Also, its recent published favorable study result on COPD buoys optimism. Over the last six months, ResMed has been observed to trade above the broader industry. However, we remain skeptical on certain fundamental factors that may weigh down the stock. In this regard, challenges like competitive bidding and reimbursement issues continue to plague the stock. Rising operating expenses and a weak operating margin are other major woes for ResMed." (10/12/2017)
  • 2. Needham & Company LLC analysts commented, "RMD’s revenue missed consensus but its EPS beat consensus in F4Q17. Organic revenue growth increased to 8% in F4Q17 from 6% in F3Q17 as RMD saw higher flow generator growth partly offset by a slowdown in masks due to supply constraints in the first two months of the quarter. While RMD’s gross margin was slightly lower than expected, it was more than offset by lower than expected SG&A and R&D allowing RMD’s operating margin to beat our estimate. We maintain our Underperform rating since we believe that RMD’s longer-run revenue growth potential is similar to its large-cap peers (mid-single digit revenue growth and 8-10% EPS growth —possibly generous since we note that RMD’s EPS growth has averaged just 4% for the past three years) while its multiple is at a premium (CY17E P/E of 26.5x vs. large-cap med tech peers at 24.3x)." (8/2/2017)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Rob Douglas, President, Chief Operating Officer
  • Michael Farrell, Chief Executive Officer, Director
  • Brett A. Sandercock, Chief Financial Officer
  • Jim Hollingshead Ph.D., President - Americas
  • Anne Reiser, President – Europe & Asia Pacific
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
  • Agnes Lee, Senior Director - Investor Relations
  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
  • Ronald R. Taylor, Lead Independent Director
  • Carol J. Burt, Independent Director

Who owns ResMed stock?

ResMed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.12%), Tandem Investment Advisors Inc. (0.06%), Shell Asset Management Co. (0.05%), Fisher Asset Management LLC (0.01%), Mutual of America Capital Management LLC (0.01%) and Eqis Capital Management Inc. (0.00%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC, Tandem Investment Advisors Inc., Rockefeller Financial Services Inc., Fisher Asset Management LLC and Eqis Capital Management Inc.. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell and Richard Sulpizio. View Insider Buying and Selling for ResMed.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was bought by a variety of institutional investors in the last quarter, including Shell Asset Management Co.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of ResMed stock can currently be purchased for approximately $79.00.


MarketBeat Community Rating for ResMed (NYSE RMD)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  591
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ResMed (NYSE:RMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 5 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.90)
Consensus Price Target: $64.80 (17.97% downside)
Consensus Price Target History for ResMed (NYSE:RMD)
Price Target History for ResMed (NYSE:RMD)
Analysts' Ratings History for ResMed (NYSE:RMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Jefferies Group LLCReiterated RatingSell$56.00N/AView Rating Details
9/25/2017Barclays PLCBoost Price TargetUnderweight -> Underweight$65.00 -> $68.00LowView Rating Details
9/8/2017Needham & Company LLCReiterated RatingSellLowView Rating Details
8/8/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
8/2/2017BMO Capital MarketsBoost Price TargetMarket Perform$61.00 -> $70.00MediumView Rating Details
8/2/2017Citigroup Inc.UpgradeNeutral -> BuyHighView Rating Details
8/2/2017Bank of America CorporationDowngradeBuy -> NeutralHighView Rating Details
4/20/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$72.00 -> $71.00MediumView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
8/29/2016Northland SecuritiesSet Price TargetSell$50.00N/AView Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralN/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for ResMed (NYSE:RMD)
Earnings by Quarter for ResMed (NYSE:RMD)
Earnings History by Quarter for ResMed (NYSE RMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$0.66N/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ResMed (NYSE:RMD)
2017 EPS Consensus Estimate: $2.71
2018 EPS Consensus Estimate: $2.94
2019 EPS Consensus Estimate: $2.55
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.57$0.64$0.61
Q2 20173$0.69$0.70$0.69
Q3 20173$0.65$0.70$0.68
Q4 20173$0.70$0.76$0.73
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.78$0.76
Q3 20182$0.72$0.75$0.74
Q4 20182$0.77$0.84$0.81
Q1 20191$0.71$0.71$0.71
Q2 20191$0.84$0.84$0.84
Q3 20191$0.81$0.81$0.81
Q4 20191$0.19$0.19$0.19
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for ResMed (NYSE:RMD)
Most Recent Dividend:9/21/2017
Annual Dividend:$1.40
Dividend Yield:1.77%
Dividend Growth:14.50% (3 Year Average)
Payout Ratio:58.09% (Trailing 12 Months of Earnings)
45.75% (Based on This Year's Estimates)
41.18% (Based on Next Year's Estimates)
Dividend Payments by Quarter for ResMed (NYSE:RMD)

Dividend History by Quarter for ResMed (NYSE RMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2017quarterly$0.351.93%8/15/20178/17/20179/21/2017
4/27/2017quarterly$0.331.94%5/9/20175/11/20176/15/2017
1/23/2017quarterly$0.331.89%2/7/20172/9/20173/16/2017
10/25/2016quarterly$0.332.18%11/8/201611/10/201612/15/2016
7/28/2016quarterly$0.331.92%8/16/20168/18/20169/22/2016
4/26/2016quarterly$0.302.12%5/17/20165/19/20166/16/2016
1/21/2016quarterly$0.302.08%2/9/20162/11/20163/17/2016
10/22/2015quarterly$0.302.13%11/17/201511/19/201512/17/2015
7/30/2015quarterly$0.302.07%8/18/20158/20/20159/17/2015
4/24/2015quarterly$0.281.7%5/19/20155/21/20156/18/2015
1/23/2015quarterly$0.281.72%2/10/20152/12/20153/19/2015
10/27/2014quarterly$0.282.17%11/18/201411/20/201412/18/2014
8/1/2014quarterly$0.282.25%8/19/20148/21/20149/18/2014
4/24/2014quarterly$0.252.11%5/16/20145/20/20146/17/2014
1/24/2014quarterly$0.252.28%2/14/20142/19/20143/19/2014
10/25/2013quarterly$0.252.02%11/15/201311/19/201312/18/2013
8/2/2013quarterly$0.252.09%8/16/20138/20/20139/17/2013
4/29/2013quarterly$0.171.44%5/17/20135/21/20136/18/2013
1/25/2013quarterly$0.171.41%2/14/20132/19/20133/19/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for ResMed (NYSE:RMD)
Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 60.10%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)
Insider Trades by Quarter for ResMed (NYSE:RMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2017Peter C FarrellDirectorSell20,000$77.01$1,540,200.00View SEC Filing  
10/3/2017David PendarvisInsiderSell6,364$76.94$489,646.16View SEC Filing  
10/2/2017Brett SandercockCFOSell1,250$77.05$96,312.50View SEC Filing  
9/5/2017David PendarvisInsiderSell6,364$77.21$491,364.44View SEC Filing  
9/5/2017Peter C FarrellDirectorSell20,000$76.74$1,534,800.00View SEC Filing  
9/1/2017Brett SandercockCFOSell1,250$77.56$96,950.00View SEC Filing  
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.50View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.40View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.50View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.00View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.04View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.34View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.00View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.30View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.75View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.00View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.43View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.50View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.35View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.00View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.31View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.40View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.96View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.75View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.00View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.57View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.52View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.00View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ResMed (NYSE:RMD)
Latest Headlines for ResMed (NYSE:RMD)
Source:
DateHeadline
fool.com logoCredit Suisse: CSL Limited shares are set to outperform
www.fool.com.au - October 19 at 8:12 AM
americanbankingnews.com logoResMed Inc. (RMD) to Release Earnings on Thursday
www.americanbankingnews.com - October 19 at 2:32 AM
americanbankingnews.com logoResMed (RMD) vs. The Competition Critical Survey
www.americanbankingnews.com - October 19 at 12:16 AM
finance.yahoo.com logoETFs with exposure to ResMed, Inc. : October 16, 2017
finance.yahoo.com - October 17 at 6:47 AM
americanbankingnews.com logoResMed Inc. (RMD) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - October 15 at 5:50 PM
americanbankingnews.com logoHead-To-Head Contrast: Varian Medical Systems (VAR) versus ResMed (RMD)
www.americanbankingnews.com - October 15 at 4:08 PM
americanbankingnews.com logoResMed Inc. (RMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:52 PM
prnewswire.com logoDaily Technical Summary Reports on Medical Equipment Stocks -- Invacare, ResMed, Stryker, and Zimmer Biomet - PR Newswire (press release)
www.prnewswire.com - October 14 at 7:23 AM
bizjournals.com logoDaily Technical Summary Reports on Medical Equipment Stocks -- Invacare, ResMed, Stryker, and Zimmer Biomet
www.bizjournals.com - October 13 at 8:48 AM
finance.yahoo.com logoResMed Wins German Patent Infringement Case Brought by Fisher & Paykel
finance.yahoo.com - October 13 at 8:48 AM
americanbankingnews.com logoResMed Inc. (RMD) Expected to Announce Earnings of $0.65 Per Share
www.americanbankingnews.com - October 12 at 2:24 AM
fool.com logoTop broker names 8 “high conviction” shares to buy now
www.fool.com.au - October 11 at 7:13 AM
finance.yahoo.com logoResMed, Inc. breached its 50 day moving average in a Bearish Manner : RMD-US : October 10, 2017
finance.yahoo.com - October 11 at 7:12 AM
americanbankingnews.com logoResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM
americanbankingnews.com logoInsider Selling: ResMed Inc. (RMD) Director Sells 20,000 Shares of Stock
www.americanbankingnews.com - October 6 at 1:20 PM
americanbankingnews.com logoInsider Selling: ResMed Inc. (RMD) Insider Sells 6,364 Shares of Stock
www.americanbankingnews.com - October 5 at 1:29 PM
americanbankingnews.com logoResMed (RMD) vs. Invivo Therapeutics Holdings Corp (NVIV) Head-To-Head Comparison
www.americanbankingnews.com - October 4 at 10:38 AM
americanbankingnews.com logoResMed Inc. (RMD) CFO Sells $96,312.50 in Stock
www.americanbankingnews.com - October 3 at 11:34 PM
seekingalpha.com logoBreathe Deeply And Buy ResMed - Seeking Alpha
seekingalpha.com - October 3 at 11:47 AM
finance.yahoo.com logoResMed, Inc. :RMD-US: Earnings Analysis: Q4, 2017 By the Numbers : October 2, 2017
finance.yahoo.com - October 3 at 11:46 AM
finance.yahoo.com logoETFs with exposure to ResMed, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 11:46 AM
finance.yahoo.com logoResMed, Inc. breached its 50 day moving average in a Bearish Manner : RMD-US : September 27, 2017
finance.yahoo.com - September 27 at 9:09 AM
americanbankingnews.com logoResMed Inc. (RMD) Price Target Raised to $68.00 at Barclays PLC
www.americanbankingnews.com - September 25 at 8:32 PM
americanbankingnews.com logo Analysts Expect ResMed Inc. (RMD) Will Announce Quarterly Sales of $500.75 Million
www.americanbankingnews.com - September 25 at 10:44 AM
americanbankingnews.com logo Analysts Expect ResMed Inc. (RMD) to Post $0.65 EPS
www.americanbankingnews.com - September 23 at 12:16 PM
americanbankingnews.com logoViveve Medical (VIVE) & ResMed (RMD) Head to Head Contrast
www.americanbankingnews.com - September 23 at 6:30 AM
americanbankingnews.com logoAnalyzing ResMed (RMD) & EnteroMedics (ETRM)
www.americanbankingnews.com - September 22 at 10:06 PM
finance.yahoo.com logoUBS has a playbook for New Zealand’s knife-edge election
finance.yahoo.com - September 19 at 7:14 AM
finance.yahoo.com logoAutomated Resupply Enrollment Now Available for HMEs Using Brightree and ResMed’s AirView
finance.yahoo.com - September 13 at 8:29 AM
americanbankingnews.com logoResMed Inc. (RMD) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 12 at 6:48 PM
nasdaq.com logoWhy Is ResMed (RMD) Up 3.1% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - September 12 at 9:19 AM
fool.com logo3 healthy US Dollar ASX shares
www.fool.com.au - September 11 at 6:26 AM
zacks.com logoWhy Is ResMed (RMD) Up 3.1% Since the Last Earnings Report?
www.zacks.com - September 11 at 6:26 AM
finance.yahoo.com logoResmed Meets 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - September 9 at 8:01 AM
americanbankingnews.com logoResMed's (RMD) "Sell" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - September 8 at 6:44 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Peter C. Farrell Sells 20,000 Shares
www.americanbankingnews.com - September 6 at 7:40 PM
americanbankingnews.com logo$500.75 Million in Sales Expected for ResMed Inc. (RMD) This Quarter
www.americanbankingnews.com - September 6 at 3:56 AM
americanbankingnews.com logoInsider Selling: ResMed Inc. (RMD) CFO Sells 1,250 Shares of Stock
www.americanbankingnews.com - September 5 at 1:17 PM
finance.yahoo.com logoResMed, Inc. breached its 50 day moving average in a Bullish Manner : RMD-US : September 1, 2017
finance.yahoo.com - September 2 at 8:11 AM
americanbankingnews.com logoReviewing Cerner Corporation (CERN) and ResMed (RMD)
www.americanbankingnews.com - August 31 at 12:23 AM
americanbankingnews.com logoResMed Inc. (RMD) Expected to Post Quarterly Sales of $500.75 Million
www.americanbankingnews.com - August 19 at 9:24 AM
finance.yahoo.com logoETFs with exposure to ResMed, Inc. : August 18, 2017
finance.yahoo.com - August 19 at 7:04 AM
americanbankingnews.com logoResMed Inc. (RMD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 18 at 6:32 PM
finance.yahoo.com logoEarnings Review and Free Research Report: ResMed Adjusted Diluted EPS Increased 4%
finance.yahoo.com - August 16 at 7:19 AM
nasdaq.com logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq
www.nasdaq.com - August 15 at 6:47 AM
nasdaq.com logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq
www.nasdaq.com - August 15 at 6:47 AM
americanbankingnews.com logoRichard Sulpizio Sells 24,390 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - August 11 at 4:20 PM
finance.yahoo.com logoCorporate News Blog - Bionix(R) Radiation Therapy Signs on Varian Medical Systems as Distributor for its Brachytherapy Applicators
finance.yahoo.com - August 11 at 8:07 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Lowered to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - August 8 at 7:34 PM
finance.yahoo.com logoResMed, Inc. :RMD-US: Earnings Analysis: 2017 By the Numbers : August 7, 2017
finance.yahoo.com - August 8 at 6:42 AM

Social

Chart

ResMed (RMD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.